Literature DB >> 20673583

Gestational trophoblastic disease.

Michael J Seckl1, Neil J Sebire, Ross S Berkowitz.   

Abstract

Gestational trophoblastic disease encompasses a range of pregnancy-related disorders, consisting of the premalignant disorders of complete and partial hydatidiform mole, and the malignant disorders of invasive mole, choriocarcinoma, and the rare placental-site trophoblastic tumour. These malignant forms are termed gestational trophoblastic tumours or neoplasia. Improvements in management and follow-up protocols mean that overall cure rates can exceed 98% with fertility retention, whereas most women would have died from malignant disease 60 years ago. This success can be explained by the development of effective treatments, the use of human chorionic gonadotropin as a biomarker, and centralisation of care. We summarise strategies for management of gestational trophoblastic disease and address some of the controversies and future research directions. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20673583     DOI: 10.1016/S0140-6736(10)60280-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  160 in total

1.  Pregnancy after oocyte donation in a patient with NLRP7 gene mutations and recurrent molar hydatidiform pregnancies.

Authors:  Claire Cozette; Florence Scheffler; Melyne Lombart; Jerome Massardier; Pierre-Adrien Bolze; Touria Hajri; Francois Golfier; Isabelle Touitou; Cecile Rittore; Jean Gondry; Philippe Merviel; Moncef Benkhalifa; Rosalie Cabry
Journal:  J Assist Reprod Genet       Date:  2020-06-26       Impact factor: 3.412

2.  Gestational trophoblastic neoplasia: treatment outcomes from a single institutional experience.

Authors:  H Al-Husaini; H Soudy; A Darwish; M Ahmed; A Eltigani; W Edesa; T Elhassan; A Omar; W Elghamry; H Al-Hashem; S Al-Hayli; I Madkhali; S Ahmad; I A Al-Badawi
Journal:  Clin Transl Oncol       Date:  2014-11-15       Impact factor: 3.405

3.  The roles of surgery and EMA/CO chemotherapy regimen in primary refractory and non-refractory gestational trophoblastic neoplasia.

Authors:  Adnan Aydiner; Serkan Keskin; Sinan Berkman; Ergin Bengisu; Huseyin Ridvan Ilhan; Faruk Tas; Erkan Topuz
Journal:  J Cancer Res Clin Oncol       Date:  2012-02-23       Impact factor: 4.553

Review 4.  The hydatidiform mole.

Authors:  Jean-Jacques Candelier
Journal:  Cell Adh Migr       Date:  2015-09-30       Impact factor: 3.405

5.  Subcutaneous mass as the primary manifestation of gestational choriocarcinoma: A case report.

Authors:  Wen-Fang Cheng; I-Hui Chen; Kuan-Ting Kuo; Li-Hui Tseng; Chi-An Chen
Journal:  Gynecol Oncol Case Rep       Date:  2011-10-26

6.  Fatal cervix rupture due to intraplacental choriocarcinoma triggered by sexual intercourse.

Authors:  Huang Weisheng; Wu Shuang; Liang Yue; Tong Fang; Dong Hongmei; Zhou Yiwu
Journal:  Int J Legal Med       Date:  2019-11-07       Impact factor: 2.686

7.  Progesterone-induced blocking factor differentially regulates trophoblast and tumor invasion by altering matrix metalloproteinase activity.

Authors:  Melinda Halasz; Beata Polgar; Gergely Berta; Livia Czimbalek; Julia Szekeres-Bartho
Journal:  Cell Mol Life Sci       Date:  2013-06-27       Impact factor: 9.261

8.  Gamma knife radiosurgery for the treatment of gynecologic malignancies metastasizing to the brain: clinical article.

Authors:  Matthew J Shepard; Francis Fezeu; Cheng-Chia Lee; Jason P Sheehan
Journal:  J Neurooncol       Date:  2014-08-17       Impact factor: 4.130

9.  Ultrasound and MRI Findings of Twin Pregnancies with Complete Hydatidiform Mole and Coexisting Normal Fetus: Two Case Reports.

Authors:  Hitomi Imafuku; Yoshiya Miyahara; Yasuhiko Ebina; Hideto Yamada
Journal:  Kobe J Med Sci       Date:  2018-05-28

10.  IgG expression in trophoblasts derived from placenta and gestational trophoblastic disease and its role in regulating invasion.

Authors:  Mei Yang; Chunfang Ha; Dan Liu; Yonghui Xu; Yuan Ma; Yufeng Liu; Yan Nian
Journal:  Immunol Res       Date:  2014-10       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.